Comparison of Transdermal and Oral Estrogens in Adolescents With Ovarian Failure
To directly compare the safety (by laboratory evaluation) and efficacy (feminization and growth) of three commonly used estrogen preparations in adolescent patients with ovarian failure, either due to congenital causes (Turner syndrome) or medical therapies. We hypothesize that transdermal estrogen will have equivalent efficacy and a more favorable safety profile in comparison with conventional oral estrogen replacement.
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- drug : 17beta Estradiol
- drug : Progesterone, micronized
- drug : 17Beta Estradiol - transdermal
- drug : Conjugated estrogens
Ages Eligible For Study:
in whom initiation of estrogen therapy has been recommended due to ovarian failure - Outpatients - age >=12 years to 17.99 years old